Reblozyl^®
(Luspatercept) Bristol-Myers Squibb

Composition:

• Available in vial that contains 25 mg of luspatercept. After reconstitution, each mL of solution contains 50 mg luspatercept

Indication(s):

• For the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy

• For the treatment of adult patients with transfusion-dependent anaemia associated with beta thalassaemia

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.